Table 6.
Oleic Acid related differences in growth outcomes among 6–10-year-old perinatally HIV-Infected, HIV-exposed uninfected and HIV-unexposed-uninfected children from Kampala, Uganda.
| Outcome | Risk Difference (p-Value) | HIV*oleic Acid | ||
|---|---|---|---|---|
| HIV Positive | Exposed | No HIV | p-Value 1 | |
| HAZ | 0.1052 | |||
| Oleic Acid Q1 vs. Q4 | 0.73 (0.008) | 0.27 (0.442) | −0.02 (0.950) | |
| Oleic Acid Q2 vs. Q4 | 0.24 (0.452) | 0.28 (0.551) | 0.61 (0.039) | |
| Oleic Acid Q3 vs. Q4 | 0.69 (0.003) | 0.44 (0.146) | −0.05 (0.868) | |
| WAZ | 0.0506 | |||
| Oleic Acid Q1 vs. Q4 | 0.95 (0.001) | 0.00 (0.997) | 0.07 (0.817) | |
| Oleic Acid Q2 vs. Q4 | 0.34 (0.252) | 0.30 (0.458) | 0.88 (0.001) | |
| Oleic Acid Q3 vs. Q4 | 0.73 (0.003) | 0.16 (0.622) | 0.47 (0.118) | |
| BAZ | 0.0879 | |||
| Oleic Acid Q1 vs. Q4 | 0.71 (0.009) | −0.11 (0.730) | −0.01 (0.987) | |
| Oleic Acid Q2 vs. Q4 | 0.29 (0.300) | 0.42 (0.185) | 0.80 (0.002) | |
| Oleic Acid Q3 vs. Q4 | 0.37 (0.279) | 0.04 (0.918) | 0.71 (0.020) | |
1P-value of interaction term of HIV and oleic acid quartiles in model from Table 5. Bolding indicates statistical significance (p< 0.05).